COX-1 (mouse) Polyclonal Antibody

Cyclooxygenase 1 (COX-1) is a bifunctional enzyme that exhibits both COX and peroxidase activities.^1,2 It is composed of an N-terminal signal peptide, an EGF-like domain, a membrane binding domain, a catalytic domain, and a C-terminal tail.³ COX-1 is constitutively expressed in the gastrointestinal tract, kidney, spleen, liver, and lung and localizes to the endoplasmic reticulum.^4,5 The COX component converts arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) to a hydroperoxyl endoperoxide prostaglandin G₂ (PGG₂; Item No. 17010) and the peroxidase component reduces the endoperoxide to the corresponding alcohol PGH₂ (Item No. 17020), the precursor of PGs, thromboxanes, and prostacyclins.^1,2 COX-1 is the target of many non-steroidal anti-inflammatory drugs (NSAIDs) and is responsible for the undesirable gastrointestinal and renal side effects, such as ulcer formation and reductions in the glomerular filtration rate, respectively.^6,7 Cayman’s COX-1 (mouse) Polyclonal Antibody can be used for Western blot (WB).

WARNING This product is not for human or veterinary use.

1. Nugteren, D.H., and Hazelhof, E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim. Biophys. Acta 326(3), 448-461 (1973).

2. Hamberg, M., and Samuelsson, B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA 70(3), 899-903 (1973).

3. Smith, W.L., and DeWitt, D.L. Prostaglandin endoperoxide H synthases-1 and -2. Adv. Immunol. 62, 167-215 (1995).

4. Seibert, K., Zhang, Y., Leahy, K., et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 91(25), 12013-12017 (1994).

5. Morita, I., Schindler, M., Regier, M.K., et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. The Journal of Biological Chemisty 270(18), 10902-10908 (1995).

6. Gierse, J.K., Hauser, S.D., Creely, D.P., et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305(Pt. 2), 379-484 (1995).

7. Frölich, J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. 18(1), 30-34 (1997).

Matsumoto, T., Kobayashi, S., Ando, M., et al. Alteration of vascular responsiveness to uridine adenosine tetraphosphate in aortas Isolated from male diabetic otsuka long-evans tokushima fatty rats: The involvement of prostanoids. Int. J. Mol. Sci. 18(11), E2378 (2017).

Björk, W., Mirrasekhian, E., Zajdel, J., et al. Cyclooxygenase isoform exchange blocks brain-mediated inflammatory symptoms. PLoS One 11(11), e0166153 (2016).

Apostoli, A.J., Skelhorne-Gross, G.E., Rubino, R.E., et al. Loss of PPARcexpression in mammary secretory epithelial cellscreates a pro-breast tumorigenic environment. Int. J. Cancer 134(5), 1055-1066 (2014).

de Faria, F.M., Luiz-Ferreira, A., Socca, E.A., et al. Effects of rhizophora mangle on experimental colitis induced by TNBS in rats. Evid Based Complement. Med. 2012, 753971 (2012).

Chia, E., Kagota, S., Wijekoon, E.P., et al. Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice. BMC Pharmacol. 11, 10 (2011).

Wu, T., Wu, H., Wang, J., et al. Expression and cellular localization of cyclooxygenases and prostaglandin E synthases in the hemorrhagic brain. J. Neuroinflammation 8, 22 (2011).

Seta, F., Rahmani, M., Turner, P.V., et al. Pulmonary oxidative stress is increased in cyclooxygenase-2- knockdown mice with mild pulmonary hypertension induced by monocrotaline. PLoS One 6(8), e23439 (2011).

Lazarus, M., Munday, C.J., Eguchi, N., et al. Immunohistochemical localization of microsomal PGE synthase-1 and cyclooxygenases in male mouse reproductive organs. Endocrinology 143(6), 2410-2419 (2002).

Kim, D.W., Chi, Y.S., Son, K.H., et al. Effects of sophoraflavanone G, a prenylated flavonoid from Sophora flavescens, on cyclooxygenase-2 and in vivo inflammatory response. Arch. Pharm. Res. 25(3), 329-335 (2002).